DOCSLIB.ORG

Current and Relevant Publications on Vitamins, Carotenoids and Other Health Ingredients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Current and Relevant Publications on Vitamins, Carotenoids and Other Health Ingredients GESELLSCHAFT FÜR ANGEWANDTE VITAMINFORSCHUNG E. V. Current and Relevant Publications on Vitamins, Carotenoids and Other Health Ingredients Update January 2012 Diese Auswahl an Publikationen aus dem Bereich der Vitamine, Mineralstoffe und sekundären Pflanzenstoffe wird von der GVF getroffen und erhebt keinen Anspruch auf Vollständigkeit. Antioxidants Long-term antioxidant supplementation has no effect on health-related quality of life: The randomized, double-blind, placebo-controlled, primary prevention SU.VI.MAX trial. Briançon S, Boini S, Bertrais S, Guillemin F, Galan P, Hercberg S. Int J Epidemiol. 2011 Dec;40(6):1605-16 Unbalanced oxidant-antioxidant status and its effects in pediatric diseases. Chiavaroli V, Giannini C, De Marco S, Chiarelli F, Mohn A. Redox Rep. 2011;16(3):101-7. doi: 10.1179/174329211X13049558293551. Review Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Lott IT, Doran E, Nguyen VQ, Tournay A, Head E, Gillen DL. Am J Med Genet A. 2011 Aug;155A(8):1939-48. doi: 10.1002/ajmg.a.34114. Epub 2011 Jul 7 Plasma antioxidants are associated with impaired lung function and COPD exacerbations in smokers. Nicks ME, O'Brien MM, Bowler RP. COPD. 2011 Aug;8(4):264-9. doi: 10.3109/15412555.2011.579202. Epub 2011 Jun 1 Methionine-induced homocysteinemia impairs endothelial function in hypertensives: the role of asymmetrical dimethylarginine and antioxidant vitamins. Tousoulis D, Bouras G, Antoniades C, Marinou K, Papageorgiou N, Miliou A, Hatzis G, Stefanadi E, Tsioufis C, Stefanadis C. Am J Hypertens. 2011 Aug;24(8):936-42. doi: 10.1038/ajh.2011.65. Epub 2011 Apr 14 Do antioxidant vitamins ameliorate the beneficial effects of exercise training on insulin sensitivity? Lavie CJ, Milani JN. Page 2 of 31 J Cardiopulm Rehabil Prev. 2011 Jul-Aug;31(4):211-6 The relationship between serum antioxidant vitamins, magnesium levels, and clinical parameters in patients with primary fibromyalgia syndrome. Sakarya ST, Akyol Y, Bedir A, Canturk F. Clin Rheumatol. 2011 Aug;30(8):1039-43. Epub 2011 Feb 24 Effects of 6 weeks of n-3 fatty acids and antioxidant mixture on lipid peroxidation at rest and postexercise. Filaire E, Massart A, Rouveix M, Portier H, Rosado F, Durand D. Eur J Appl Physiol. 2011 Aug;111(8):1829-39. Epub 2011 Jan 11 Is oxidative stress a therapeutic target in cardiovascular disease? Münzel T, Gori T, Bruno RM, Taddei S. Eur Heart J. 2010 Nov;31(22):2741-8. Epub 2010 Oct 25. Review Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia. Matsuzawa D, Hashimoto K. Antioxid Redox Signal. 2011 Oct 1;15(7):2057-65. Epub 2010 Dec 4. Review Vitamin A Newborn vitamin A supplementation does not affect nasopharyngeal carriage of Streptococcus pneumoniae in Bangladeshi infants at age 3 months. Coles CL, Labrique A, Saha SK, Ali H, Al-Emran H, Rashid M, Christian P, West KP Jr, Klemm R. J Nutr. 2011 Oct;141(10):1907-11. Epub 2011 Aug 10 Vitamin A and retinoid derivatives for lung cancer: a systematic review and meta analysis. Fritz H, Kennedy D, Fergusson D, Fernandes R, Doucette S, Cooley K, Seely A, Sagar S, Wong R, Seely D. PLoS One. 2011;6(6):e21107. Epub 2011 Jun 27. Review Vitamin A dynamics in breastmilk and liver stores: a life history perspective. Fujita M, Shell-Duncan B, Ndemwa P, Brindle E, Lo YJ, Kombe Y, O'Connor K. Am J Hum Biol. 2011 Sep-Oct;23(5):664-73. doi: 10.1002/ajhb.21195. Epub 2011 Jun 21 Zinc, vitamin A, and micronutrient supplementation in children with diarrhea: a randomized controlled clinical trial of combination therapy versus monotherapy. Dutta P, Mitra U, Dutta S, Naik TN, Rajendran K, Chatterjee MK. J Pediatr. 2011 Oct;159(4):633-7. Epub 2011 May 17 Vitamin A and E status in very low birth weight infants. Kositamongkol S, Suthutvoravut U, Chongviriyaphan N, Feungpean B, Page 3 of 31 Nuntnarumit P. J Perinatol. 2011 Jul;31(7):471-6. doi: 10.1038/jp.2010.155. Epub 2011 Jan 13 Vitamin A supplementation at birth might prime the response to subsequent vitamin A supplements in girls. Three year follow-up of a randomized trial. Fisker AB, Aaby P, Rodrigues A, Frydenberg M, Bibby BM, Benn CS. PLoS One. 2011;6(8):e23265. Epub 2011 Aug 11 B-Vitamins Maternal nutritional status, C1 metabolism and offspring DNA methylation: a review of current evidence in human subjects. Dominguez-Salas P, Cox SE, Prentice AM, Hennig BJ, Moore SE. Proc Nutr Soc. 2011 Nov 29:1-12. [Epub ahead of print] B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP). Schernhammer ES, Giovannucci E, Baba Y, Fuchs CS, Ogino S. PLoS One. 2011;6(6):e21102. Epub 2011 Jun 27 B vitamin status, dietary intake and length of stay in a sample of elderly rehabilitation patients. O'Leary F, Flood VM, Petocz P, Allman-Farinelli M, Samman S. J Nutr Health Aging. 2011;15(6):485-9 The role of preoperative oral vitamin B in the cystoscopic assessment of ureteric patency. Fernando S, Dowling C, Rosamilia A. Int Urogynecol J. 2011 Aug;22(8):947-51. Epub 2011 Apr 7 Vitamin B1 Does early treatment prevent deafness in thiamine-responsive megaloblastic anaemia syndrome? $N×Q/.XUWRÿOX6.HQGLUFL0$N×Q0$.DUDNNo M. J Clin Res Pediatr Endocrinol. 2011;3(1):36-9. Epub 2011 Feb 23 Cardiovascular magnetic resonance in wet beriberi. Essa E, Velez MR, Smith S, Giri S, Raman SV, Gumina RJ. J Cardiovasc Magn Reson. 2011 Aug 12;13:41 Vitamin B12 Vitamin B(12) deficiency as a cause of delirium in a patient with spinal cord injury. Harrington AL, Dixon TM, Ho CH. Page 4 of 31 Arch Phys Med Rehabil. 2011 Nov;92(11):1917-20 Vitamin B-12 and homocysteine status in a folate-replete population: results from the Canadian Health Measures Survey. MacFarlane AJ, Greene-Finestone LS, Shi Y. Am J Clin Nutr. 2011 Oct;94(4):1079-87. Epub 2011 Sep 7 Low maternal vitamin B-12 status is associated with offspring insulin resistance regardless of antenatal micronutrient supplementation in rural Nepal. Stewart CP, Christian P, Schulze KJ, Arguello M, LeClerq SC, Khatry SK, West KP Jr. J Nutr. 2011 Oct;141(10):1912-7. Epub 2011 Aug 24 Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2- hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single- dose, parallel-group study in healthy male subjects. Castelli MC, Wong DF, Friedman K, Riley MG. Clin Ther. 2011 Jul;33(7):934-45. Epub 2011 Jul 1 Juvenile selective vitamin B12 malabsorption: 50 years after its description- 10 years of genetic testing. Gräsbeck R, Tanner SM. Pediatr Res. 2011 Sep;70(3):222-8. Review Vitamin B2 A randomised, prospective study to investigate the efficacy of riboflavin/ultraviolet A (370 nm) corneal collagen cross-linkage to halt the progression of keratoconus. O'Brart DP, Chan E, Samaras K, Patel P, Shah SP. Br J Ophthalmol. 2011 Nov;95(11):1519-24. Epub 2011 Feb 24 Vitamin B6 Dietary intake of vitamin B(6) and risk of breast cancer in Taiwanese women. Chou YC, Chu CH, Wu MH, Hsu GC, Yang T, Chou WY, Huang HP, Lee MS, Yu CP, Yu JC, Sun CA. J Epidemiol. 2011 Sep 5;21(5):329-36. doi: 10.2188/jea.JE20100188. Epub 2011 Jun 25 Higher plasma pyridoxal 5'-phosphate is associated with better blood glucose responses in critically ill surgical patients with inadequate vitamin B-6 status. Hou CT, Wu YH, Huang PN, Cheng CH, Huang YC. Clin Nutr. 2011 Aug;30(4):478-83. Epub 2011 Feb 23 Page 5 of 31 Intakes of vitamin B6 and dietary fiber and clinical course of systemic lupus erythematosus: a prospective study of Japanese female patients. Minami Y, Hirabayashi Y, Nagata C, Ishii T, Harigae H, Sasaki T. J Epidemiol. 2011 Jul 5;21(4):246-54. Epub 2011 Apr 23 Vitamin B(6) salvage enzymes: mechanism, structure and regulation. di Salvo ML, Contestabile R, Safo MK. Biochim Biophys Acta. 2011 Nov;1814(11):1597-608. Epub 2010 Dec 20. Review Biotin Early evolution of the biotin-dependent carboxylase family. Lombard J, Moreira D. BMC Evol Biol. 2011 Aug 9;11:232 Folic acid Modulatory effect of plasma folate and polymorphisms in one-carbon metabolism on catecholamine methyltransferase (COMT) H108L associated oxidative DNA damage and breast cancer risk. Naushad SM, Pavani A, Rupasree Y, Sripurna D, Gottumukkala SR, Digumarti RR, Kutala VK. Indian J Biochem Biophys. 2011 Aug;48(4):283-9 Estimating the impact of mandatory folic acid fortification on the folic acid intake of Australian women of childbearing age. Emmett JK, Lawrence M, Riley M. Aust N Z J Public Health. 2011 Oct;35(5):442-50. doi: 10.1111/j.1753- 6405.2011.00759.x Preschool iron-folic acid and zinc supplementation in children exposed to iron-folic acid in utero confers no added cognitive benefit in early school- age. Christian P, Morgan ME, Murray-Kolb L, LeClerq SC, Khatry SK, Schaefer B, Cole PM, Katz J, Tielsch JM. J Nutr. 2011 Nov;141(11):2042-8. Epub 2011 Sep 28 Metabolic signature of pregnant women with neural tube defects in offspring. Zheng X, Su M, Pei L, Zhang T, Ma X, Qiu Y, Xia H, Wang F, Zheng X, Gu X, Song X, Li X, Qi X, Chen G, Bao Y, Chen T, Chi Y, Zhao A, Jia W. J Proteome Res. 2011 Oct 7;10(10):4845-54. Epub 2011 Sep 22 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition.
Load more

Recommended publications
  • WO 2U11/154U12 a L
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 15 December 2011 (15.12.2011) WO 2U11/154U12 A l (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/415 (2006.01) A61K 9/20 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/DK201 1/050207 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 10 June 201 1 (10.06.201 1) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: PA 2010 00506 10 June 2010 (10.06.2010) DK Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): LIFE- GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, CYCLE PHARMA A S [DK/DK]; Kogle Alle 4, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, DK-2970 H0rsholm (DK).
    [Show full text]
  • Principios Activos Fotosensibles
    PRINCIPIOS ACTIVOS FOTOSENSIBLES PROTEGE A TUS PRODUCTOS DE LA FOTODEGRADACIÓN PRINCIPIOS ACTIVOS FOTOSENSIBLES Adenosine Carbamazepine Digitoxin Heptacaine Methaqualone-1-oxide Phenothiazines Sulfisomidine Tinidazole Vitamin D Adrenaline Carbisocaine Digoxin Hexachlorophane Methotrexate Phenylbutazone Sulpyrine Tolmetin Vitamin E Adriamycin Carboplatin Dihydroergotamin Hydralazine Metronidazole Phenylephrine Suprofen Tretinoin Vitamin K1 Amidopyrin Carmustine Dihydropyridines Mifepristone Phenytoin Triamcinolone Vitamin K2 Hydrochlorothiazide Suramin Amidinohydrazones Cefotaxime Diltiazem Hydrocortisone Minoxidil Physostigmine Triamterene Warfarin Amiloride Cefuroxime axetil Diosgenin Mitomycin C Piroxicam Tauromustine (TCNU) Trifluoperazine Hydroxychloroquine Terbutaline 4-Aminobenzoic acid Cephaeline Diphenhydramine Hypochloride Mitonafide Pralidoxime Trimethoprim Aminophenazone Cephalexine Dipyridamole Ibuprofen Mitoxantrone Prednisolone Tetracyclines Ubidecarenone Thiazide Aminophylline Cephradine Dithranol Imipramin Molsidomine Primaquine Vancomycin Thiocolchicoside Aminosalicylic acid Chalcone Dobutamin Indapamide Morphine Proguanil Vinblastine Thioridazine Amiodarone Chloramphenicol Dopamine Indomethacin Nalidixic acid Promazine Vitamin A Thiorphan Amodiaquine Chlordiazepoxide Dothiepin Indoprofen Naproxen Promethazine Vitamin B (see also Thiothixene Amonafide Chloroquine Doxorubicin Isoprenaline Neocarzinostatin Proxibarbital riboflavine) Tiaprofenic acid Amphotericin B Chlorpromazine DTIC Isopropylamino- Nimodipine Psoralen
    [Show full text]
  • Promotion of Bone Formation by Fermented Soybean (Natto) Intake in Premenopausal Women
    J Nutr Sci Vitaminol, 50,114-120, 2004 Promotion of Bone Formation by Fermented Soybean (Natto) Intake in Premenopausal Women Hironobu KATSUYAMA1,Seiji IDEGUCHI2,Masao FUKUNAGA3, Tatsushige FUKUNAGA4, Kiyofumi SAIJOHSand Shigeo SUNAMII Departments of 1Public Health, 2Health Care Medicine arid 3NuclearMedicine , Kawasaki Medical School,Kurashiki 701-0192, Japan 4Departrnent of Forensic Medicine and Sciences , Mie University School of Medicine, Tsu 514-8507, Japan 5Department of Hygiene , Kanazawa University School of Medicine and Graduate School of Medical Sciences, Kanazawa 920-8640, Japan (Received July 24, 2003) Summary A therapeutic agent of vitamin K2 is approved for the treatment of osteoporosis in Japan. However, little is known about the efficacy of dietary intake of vitamin K2for bone health. We compared the effects of various levels of fermented soybeans (Natto) intake , which contains plenty of vitamin K2, on bone stiffness and bone turnover markers in healthy premenopausal women, Seventy-three healthy premenopausal women were ran domly divided into four groups matched for age and parity categories . Natto was supplied as follows: Group 1(no intake), Group 2 (once per month), Group 3 (once per week) and Group 4 (three times per week). Subjects took Natto at a lunch for 1 y, and the stiffness index by quantitative ultrasound and bone turnover markers were assessed at baseline, 6 mo and 1 y There was no statistical difference in the stiffness index during the 1 y observation . How ever, bone specific alkaline phosphatase (BAP) in Group 4 was higher than that in Group 3 at 1 y and undercarboxylated osteocalcin (Glu) in Group 4 was significantly lower than those in Groups 1, 2 and 3 at 6 mo.
    [Show full text]
  • Pharmaceuticals and Medical Devices Safety Information No
    Pharmaceuticals and Medical Devices Safety Information No. 215 July 2005 Table of Contents 1. Important Safety Information ································································ 2 .1. Ethionamide ······················································································ 2 .2. Etodolac ···························································································· 5 .3. Gemcitabine Hydrochloride ····························································· 10 .4. Omeprazole, Omeprazole Sodium ·················································· 12 2. Revision of PRECAUTIONS (No.167) Tiaprofenic Acid (and 17 others) ·································································· 16 3. List of products subject to Early Post-marketing Phase Vigilance ·············································· 23 This Pharmaceuticals and Medical Devices Safety Information (PMDSI) is issued based on safety information collected by the Ministry of Health, Labour and Welfare. It is intended to facilitate safer use of pharmaceuticals and medical devices by healthcare providers. PMDSI is available on the Pharmaceuticals and Medical Devices Agency website (http://www.pmda.go.jp/english/index.html) and on the MHLW website (http://www.mhlw.go.jp/, Japanese only). Published by Translated by Pharmaceutical and Food Safety Bureau, Pharmaceuticals and Medical Devices Agency Ministry of Health, Labour and Welfare Pharmaceutical and Food Safety Bureau, Office of Safety, Ministry of Health, Labour and Welfare Pharmaceuticals and Medical
    [Show full text]
  • Application of Marsplines and Descriptors Encoded in SMILES String
    Supplementary Materials Predicting value of binding constants of organic ligands to beta-cyclodextrin: application of MARSplines and descriptors encoded in SMILES string Piotr Cysewski1 and Maciej Przybyłek1,* 1 Chair and Department of Physical Chemistry, Faculty of Pharmacy, Collegium Medicum of Bydgoszcz, Nicolaus Copernicus University in Toruń, Kurpińskiego 5, 85-950 Bydgoszcz, Poland; [email protected] Table. S1 Experimental and calculated LnK values. No. Chemical name SMILES lnKexp* lnKest Set (ext. validation) 1 Acetonitrile CC#N -1.474 -1.278 test 2 Methanol CO -1.128 -1.235 training 3 Acetaldehyde CC=O -0.622 -0.225 training 4 1,2-Ethanediol C(CO)O -0.437 0.828 training 5 Ethanol CCO -0.069 0.504 training 6 2-Methoxyethanol COCCO 0.507 0.711 test 7 Acetone CC(=O)C 0.967 0.619 training 8 1-Propanol CCCO 1.312 1.410 training 9 2-Propanol CC(C)O 1.451 1.988 training 10 1,4-Butanediol C(CCO)CO 1.474 2.177 training 11 1,3-Propanediol C(CO)CO 1.543 1.512 test 12 Cyclobutanol C1CC(C1)O 2.717 3.234 training 13 2-Butanol CCC(C)O 2.740 2.849 training 14 1-Butanol CCCCO 2.809 2.739 training 15 1,5-Pentanediol C(CCO)CCO 2.809 2.860 training 1 No. Chemical name SMILES lnKexp* lnKest Set (ext. validation) 16 3-Pentanol CCC(CC)O 3.108 4.305 test 17 Diethylamine CCNCC 3.132 2.355 training 18 Chloroform C(Cl)(Cl)Cl 3.293 3.119 training 19 Tetrahydrofuran C1CCOC1 3.385 2.874 training 20 Griseofulvin C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(= 3.385 3.929 training C(C=C3OC)OC)Cl)OC 21 2-Pentanol CCCC(C)O 3.431 4.916 training 22 3-Cyanophenylacetate
    [Show full text]
  • Commmon Factors for Parkinson's Disease and Crohn's Disease
    © The MITRE Corporation. All rights reserved LITERATURE-RELATED DISCOVERY: COMMON FACTORS FOR PARKINSON’S DISEASE AND CROHN’S DISEASE Dr. Ronald N. Kostoff The MITRE Corporation 7515 Colshire Drive McLean, VA 22102 DISCLAIMER (The views contained in this paper are solely those of the author and do not reflect the views of the MITRE Corporation) ACKNOWLEDGEMENT This project was supported by MITRE internal research funding. KEYWORDS Literature-related discovery; Text mining; Scientometrics; Parkinson‟s disease; Crohn‟s disease; neurodegeneration; autoimmunity; inflammation © The MITRE Corporation. All rights reserved ABSTRACT Literature-related discovery (LRD) is the linking of two or more literature concepts that have heretofore not been linked (i.e., disjoint), in order to produce novel, interesting, and intelligible knowledge (i.e., potential discovery). The mainstream software for assisting LRD is Arrowsmith, and it generates intermediate linking literatures by matching title phrases from two disjoint literatures (literatures that do not share common records). Arrowsmith then prioritizes these linking phrases through a series of text-based filters. The present study examines another route to linking disjoint literatures (shared references) through a process called bibliographic coupling. Two disjoint literatures were selected: Parkinson‟s Disease (PD) (neurodegeneration) and Crohn‟s Disease (CD)(autoimmune). Three cases were examined: matching phrases in records with no shared references; shared references in records with no matching phrases; matching phrases in records with shared references. In addition, the main themes in the body of shared references were examined through grouping techniques to identify the myriad linkages between the two literatures. No concepts were identified in the matching phrases/no shared references records that could not be found in the matching phrases/shared references records.
    [Show full text]
  • Vitamin K Monograph
    Vitamin K Natural Standard Bottom Line Monograph, Copyright © 2008 (www.naturalstandard.com). Commercial distribution prohibited. This monograph is intended for informational purposes only, and should not be interpreted as specific medical advice. You should consult with a qualified healthcare provider before making decisions about therapies and/or health conditions. While some complementary and alternative techniques have been studied scientifically, high-quality data regarding safety, effectiveness, and mechanism of action are limited or controversial for most therapies. Whenever possible, it is recommended that practitioners be licensed by a recognized professional organization that adheres to clearly published standards. In addition, before starting a new technique or engaging a practitioner, it is recommended that patients speak with their primary healthcare provider(s). Potential benefits, risks (including financial costs), and alternatives should be carefully considered. The below monograph is designed to provide historical background and an overview of clinically-oriented research, and neither advocates for or against the use of a particular therapy. Related Terms: 2-methyl-1,4-naphthoquinone, AquaMEPHYTON®, Konakion®, menadiol (not available in United States), menadiol diphosphate (vitamin K3), menadione, menaquinones, menatetrenone, Mephyton®, Phylloquinone®, Phytomenadione®, phytonadione. The name "vitamin K" refers to a group of chemically similar fat-soluble compounds called naphthoquinones. Vitamin K1 (phytonadione) is the natural form of vitamin K, which is found in plants and provides the primary source of vitamin K to humans through dietary consumption. Vitamin K2 compounds (menaquinones) are made by bacteria in the human gut and provide a smaller amount of the human vitamin K requirement. Vitamin K1 is commercially manufactured for medicinal use under several brand names (Phylloquinone®, Phytonadione®, AquaMEPHYTON®, Mephyton®, Konakion®).
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Menatetrenone, a Vitamin K2 Analogue, Inhibits Hepatocellular
    Cancer Therapy: Preclinical Menatetrenone, a Vitamin K2 Analogue, Inhibits Hepatocellular Carcinoma Cell Growth by Suppressing Cyclin D1 Expression through Inhibition of Nuclear Factor KBActivation Iwata Ozaki,1, 2 Hao Zhang,1, 3 To s hi hi ko Mi z u t a , 1Ya s u s hi Id e ,1Yuichiro Eguchi,1TsutomuYasutake,1 Toshiyuki Sakamaki,4 Richard G. Pestell,4 and KyosukeYamamoto1 Abstract Purpose: Menatetrenone, a vitamin K2 analogue, plays an important role in the production of blood coagulation factors. Menatetrenone has also bee shown to have antineoplastic effects against several cancer cell lines including hepatocellular carcinoma (HCC) cells. However, the mechanisms by which vitamin K2 inhibits HCC cell growth have not bee fully clarified, and we therefore investigated the molecular basis of vitamin K2^ induced growth inhibition of HCC cells. Experimental Design: HCC cells were treated with vitamin K2 and the expression of several growth-related genes including cyclin-dependent kinase inhibitors and cyclin D1 was examined at the mRNA and protein levels. A reporter gene assay of the cyclin D1promoter was done under vitamin K2 treatment.The regulation of nuclear factor nB(NF-nB) activation was investigated by aNF-nB reporter gene assay, an electrophoretic mobility shift assay, aWestern blot for phosphor- ylated InB, and an in vitro kinase assay for InB kinase (IKK).We also examined the effect of vitamin K2 on the growth of HCC cells transfected with p65 or cyclin D1. Results:Vitamin K2 inhibited cyclin D1mRNA and protein expression in a dose-dependent man- ner in the HCC cells. Vitamin K2 also suppressed the NF-nB binding site-dependent cyclin D1 promoter activity and suppressed the basal, 12-O-tetradecanoylphorbol-13-acetate (TPA)^, TNF-a^, and interleukin (IL)-1^ induced activation of NF-nB binding and transactivation.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0064805 A1 Obae Et Al
    US 2011 OO64805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0064805 A1 Obae et al. (43) Pub. Date: Mar. 17, 2011 (54) POROUS CELLULOSE AGGREGATE AND Publication Classification MOLDING COMPOSITION THEREOF (51) Int. Cl. (75) Inventors: Kazuhiro Obae, Tokyo (JP); A69/20 (2006.01) HidekiO O Amakawa, Tokyo (JP); A6IR 9/16 (2006.01) Ichirochiro Ibuki,Ibuki.T Tokyo (JP)JP A6II 3/663/167 (2006.01) (73) Assignee: ASAHIKASE CHEMICALS A63L/92A6II 3/34 308:2006.O1 CORPORATION, Tokyo (JP) CI3K L/02 (2006.01) 21) Appl. No.: 12A926,318 (52) U.S. Cl. ......... 424/464; 424/499; 514/630; 514/622: (21) Appl. No 9 514/474; 514/570; 127/34; 127/37 (22) Filed: Nov. 9, 2010 (57) ABSTRACT Related U.S. Application Data A porous cellulose aggregate characterized by having a sec - - - ondary aggregate structure resulting from aggregation of pri (62) Division of application No. 11/918,979, filed on Oct. mary cellulose particles, having a pore Volume within a par 22, 2007, filed as application No. PCT/JP2006/308414 ticle of 0.265 to 2.625 cm/g, containing I-type crystals and on Apr. 21, 2006. having an average particle size of over 30 to 250 Lim, a specific surface area of 0.1 to less than 20 m/g, a repose angle of 25° (30) Foreign Application Priority Data to less than 44° and a swelling degree of 5% or more, and characterized by having the property of disintegrating in Apr. 22, 2005 (JP) ................................. 2005-124477 Water. Patent Application Publication Mar.
    [Show full text]
  • WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
    WHO/EMP/RHT/TSN/2018.1 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization [2018] Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]
  • Test Catalog and Fee Schedule
    TEST CATALOG AND FEE SCHEDULE Salt Lake City Laboratory www.alsglobal.com 1-800-356-9135 Table of Contents Industrial Hygiene Fee Schedule Qualifications and Accreditations, Description of Services, Rush Services .............................. IH-iii Lists of Analyses by Method Alphabetical ........................................................................................................................ IH-1 NIOSH Methods ................................................................................................................ IH-13 OSHA Methods ................................................................................................................. IH-17 Common Industrial Hygiene Analyses .............................................................................. IH-19 Analyte Lists for Common Industrial Hygiene Analyses ................................................... IH-27 ALS Environmental —Salt Lake City Standard Industrial Hygiene Report Formats ............... IH-33 Media Available from ALS Environmental (Salt Lake City). .................................................... IH-35 Sampling Equipment Rentals from ALS Environmental (Salt Lake City). ............................... IH-39 Microbiological Services ....................................................................................................... MS-1 Dietary Supplements ................................................................................................................................................................. DS-1 Periodic
    [Show full text]